At a glance
ClinicalIndex Comparison RecordN/ACompleted· 38 enrolled
Drug / intervention
Karius Testother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Plasma-Based Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
In Brief
A clinical study evaluating Karius Test for Musculoskeletal Infection and 4 related conditions. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the use of a blood test: Karius® plasma-based next-generation sequencing test (Karius Test), to see if we can detect and measure the infection causing agent in children with musculoskeletal infections (MSKI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMusculoskeletal Infection, Acute Hematogenous Osteomyelitis, Septic Arthritis, Osteomyelitis, Pyomyositis
CountriesUnited States
CollaboratorsKarius, Inc.
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartSep 2019
Primary CompletionJun 2022
TodayJul 2026
First PostedFeb 20, 2019
Enrollment StartSep 1, 2019
Primary CompletionJun 2, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7.4 years ago
Interventions
Karius Testother
Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections